All In Biotech

Drug Trial Radar · NCT06083207

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

A Phase I/II, Multicenter, Open-label, First-in-human Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

116

Planned (sponsor's estimate)

Start

Jul 29, 2024

Primary completion

Oct 31, 2026

Study completion Oct 31, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 23\~116 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • IBI3003Drug

    Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs)Time frame: Up to 30 days post last dose

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Wollongong Private Hospital

    Wollongong, New South Wales, Australia · Suspended

  • Austin Hospital

    Heidelberg, Victoria, Australia · Suspended

  • St Vincent's Hospital

    Melbourne, Victoria, Australia · Suspended

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The first Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

  • Tongji Medical College of HUST Tongji Hospital

    Wuhan, Hubei, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Not yet recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • ZhongShan Hospital FuDan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • The First Affiliated Hospital of XI'AN Jiaotong University

    Xian, Shanxi, China · Not yet recruiting

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.